Company / EPS (Diluted)
BioLife Solutions, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.10
FY2025
5-year range
-$3.25 / -$0.10
FY2021-FY2025
Trend
+77.3%
vs FY2024
Sector context
#94 of 159
Health Care
What the data says
At $-0.10, BioLife Solutions, Inc.'s eps (diluted) ranks #94 of 159 in the Health Care sector. EPS (Diluted) has increased for 3 consecutive years, from $-3.25 in FY2022 to $-0.10 in FY2025.
Based on SEC 10-K filings.
-0.10 in FY2025.
Improved from $-1.55 to $-0.10 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 159 in Health CareTop 59% of 159This company -$0.10 Sector average $1.66
▼
-106.0% below sector average
Key checks
Key Insights
- BioLife Solutions, Inc.'s eps (diluted) has grown for 3 consecutive years.
- In FY2025, eps (diluted) increased 77.3% year-over-year.
- Ranks #94 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.10 | +77.3% |
| FY2024 | -$0.44 | +71.6% |
| FY2023 | -$1.55 | +52.3% |
| FY2022 | -$3.25 | -1313.0% |
| FY2021 | -$0.23 | -283.3% |
| FY2020 | -$0.06 | +33.3% |
| FY2019 | -$0.09 | +93.9% |
| FY2018 | -$1.48 | -174.1% |
| FY2017 | -$0.54 | -54.3% |
| FY2016 | -$0.35 | -12.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026